The worldwide epidemic of type 2diabetes and increasing obesity are leading to the increasing prevalence of non-alcoholic steatohepatitis (NASH), particularly in the developed economies. According to the NASH Education The program, NASH distresses approximately 12% of the world's adult populace. More than 80% of patients with NASH are obese, 44% have type 2 diabetes, and 72% have abnormal blood lipids (triglycerides and cholesterol). The effective rise in the prevalence of these ailments is anticipated to foster the requirement for the NASH diagnostics over the 2018-2023 periods.
In addition, the programs, and initiatives to effectively increase awareness are predicted to positively foster market growth over the forecast duration. In 2016, The NASH Education Program was developed with the objective of spreading consciousness among medical practitioners, patients identified with NASH, and personalities at high risk of developing it. On the other hand, augmenting the investments for the development of precise, reliable and willingly obtainable diagnostic tests for NASH is expected to foster the market over the forecast duration.
According to the report analysis, ‘Global Non-alcoholic Steatohepatitis (NASH) Diagnostics Market (2018-2023)’ states that in the worldwide Non-alcoholic Steatohepatitis (NASH) diagnostics market, there is an effective number of players for leading the fastest market growth and registering the handsome value of market share around the globe during the short span of time while developing the benefits of the product, leading the consciousness across the globe throughout the short span of time, delivering better consumer satisfaction and decreasing the cost of productivity includes GENFIT SA, Echosens, SuperSonic Imagine, BioPredictive, One Way Liver, S.L. (OWL), VLVbio AB, Quest Diagnostics Incorporated, Prometheus Laboratories Inc., Siemens Healthcare GmbH, Exalenz Bioscience Ltd., and several others.
Additionally, based on the diagnostic techniques segment, the Liver biopsy is one of the widely adopted diagnostic techniques for NASH detection since it delivers accurate results. The Liver biopsy is favored by the medical consultants due to its capability to regulate the degree of steatosis and inflammation correctly. However, the aggressive liver biopsy process has numerous disadvantages, such as pain, bleeding, and the opportunity of injuring other organs. Thus, the implementation of the non-invasive imaging techniques and biomarkers is predicted to augment significantly. As a result, the market size of the liver biopsy technique is anticipated to increase at a leisurelier rate than biomarkers, in developed economies like North America and Europe.
For instance, the great cost of NASH diagnosis through liver biopsy is hindering the growth of the market in developing economies like Latin America and Asia-Pacific. On the basis of regional insights, North America controlled the principal share of the NASH diagnostics market. The increasing pervasiveness of obesity and type 2 diabetes is leading to an augmenting the number of patients anguish from NASH in the United States (U.S.) and Canada. NASH has been described to be the second-most common source for liver transplantations in the U.S. By 2020, it is anticipated to exceed hepatitis C as the leading cause of liver transplants. Not only has this, but the Asia-Pacific is also predicted to be the fastest increasing market owing to the growing awareness among patients and developing the healthcare infrastructure. Therefore, in the coming years, it is predicted that the market of non-alcoholic steatohepatitis diagnostic will increase around the world more positively over the near years.
Companies covered:-
GENFIT SA
Echosens
SuperSonic Imagine
BioPredictive
One Way Liver
VLVbio AB
Quest Diagnostics Incorporated
Prometheus Laboratories Inc
Siemens Healthcare GmbH
Exalenz Bioscience Ltd
To Know More, Click On The Link Below:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
